Ultragenyx Pharmaceutical Inc. (RARE) Social Stream
ULTRAGENYX PHARMACEUTICAL INC (RARE) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering RARE.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-01-05 | 16 | $185 | $73 | $146.2 | $46.15 | 216.79% |
| 2022-01-11 | 16 | $185 | $73 | $143.933 | $46.15 | 211.88% |
| 2022-01-25 | 16 | $185 | $73 | $143 | $46.15 | 209.86% |
| 2022-01-26 | 16 | $185 | $73 | $142.4 | $46.15 | 208.56% |
| 2022-01-31 | 16 | $185 | $73 | $140 | $46.15 | 203.36% |
| 2022-02-11 | 16 | $185 | $73 | $140 | $46.15 | 203.36% |
| 2022-02-14 | 15 | $185 | $73 | $139.466 | $46.15 | 202.2% |
| 2022-04-26 | 15 | $186 | $73 | $139.533 | $46.15 | 202.35% |
| 2022-04-28 | 15 | $186 | $73 | $139.666 | $46.15 | 202.63% |
| 2022-05-05 | 15 | $186 | $73 | $138.461 | $46.15 | 200.02% |
| 2022-05-09 | 13 | $186 | $71 | $129.538 | $46.15 | 180.69% |
| 2022-05-18 | 14 | $186 | $71 | $126.846 | $46.15 | 174.86% |
| 2022-05-24 | 14 | $186 | $71 | $125 | $46.15 | 170.86% |
| 2022-07-28 | 13 | $185 | $70 | $121.5 | $46.15 | 163.27% |
| 2022-08-01 | 14 | $185 | $68 | $117 | $46.15 | 153.52% |
| 2022-08-02 | 14 | $185 | $60 | $112.666 | $46.15 | 144.13% |
| 2022-08-13 | 14 | $185 | $60 | $114.5 | $46.15 | 148.1% |
| 2022-09-17 | 12 | $185 | $60 | $117.266 | $46.15 | 154.1% |
| 2022-10-12 | 11 | $185 | $60 | $117.266 | $46.15 | 154.1% |
| 2022-10-21 | 13 | $185 | $50 | $112 | $46.15 | 142.69% |
| 2022-10-25 | 13 | $185 | $50 | $111.5 | $46.15 | 141.6% |
| 2022-11-03 | 14 | $164 | $49 | $102.312 | $46.15 | 121.69% |
| 2022-11-04 | 14 | $143 | $49 | $101 | $46.15 | 118.85% |
| 2022-12-07 | 14 | $143 | $49 | $98.125 | $46.15 | 112.62% |
| 2022-12-13 | 14 | $143 | $49 | $94.937 | $46.15 | 105.71% |
| 2023-01-13 | 15 | $143 | $49 | $94.176 | $46.15 | 104.07% |
| 2023-01-26 | 15 | $143 | $48 | $94.117 | $46.15 | 103.94% |
| 2023-01-27 | 15 | $143 | $48 | $92.823 | $46.15 | 101.13% |
| 2023-02-01 | 15 | $143 | $48 | $92.823 | $46.15 | 101.13% |
| 2023-02-16 | 15 | $143 | $48 | $92.529 | $46.15 | 100.5% |
| 2023-02-21 | 15 | $142 | $47 | $91.823 | $46.15 | 98.97% |
| 2023-04-17 | 15 | $142 | $47 | $91.588 | $46.15 | 98.46% |
| 2023-04-24 | 15 | $142 | $47 | $91.47 | $46.15 | 98.2% |
| 2023-05-05 | 16 | $142 | $47 | $92.722 | $46.15 | 100.91% |
| 2023-05-08 | 16 | $142 | $48 | $91.888 | $46.15 | 99.11% |
| 2023-05-11 | 16 | $142 | $48 | $91.777 | $46.15 | 98.87% |
| 2023-05-23 | 16 | $142 | $48 | $92 | $46.15 | 99.35% |
| 2023-06-06 | 17 | $142 | $50 | $93.277 | $46.15 | 102.12% |
| 2023-06-28 | 17 | $140 | $50 | $92.777 | $46.15 | 101.03% |
| 2023-07-24 | 17 | $140 | $49 | $92.666 | $46.15 | 100.79% |
| 2023-08-04 | 17 | $140 | $49 | $91.941 | $46.15 | 99.22% |
| 2023-08-07 | 17 | $140 | $47 | $91.352 | $46.15 | 97.95% |
| 2023-09-26 | 17 | $140 | $47 | $91.588 | $46.15 | 98.46% |
| 2023-10-12 | 17 | $140 | $47 | $91.294 | $46.15 | 97.82% |
| 2023-10-17 | 16 | $140 | $47 | $91.294 | $46.15 | 97.82% |
| 2023-10-23 | 17 | $140 | $43 | $92.444 | $46.15 | 100.31% |
| 2023-11-03 | 17 | $140 | $43 | $92.611 | $46.15 | 100.67% |
| 2023-11-06 | 17 | $140 | $43 | $91.888 | $46.15 | 99.11% |
| 2023-11-24 | 17 | $140 | $43 | $91.777 | $46.15 | 98.87% |
| 2023-12-04 | 17 | $140 | $43 | $91.388 | $46.15 | 98.02% |
| 2023-12-08 | 18 | $140 | $43 | $90.368 | $46.15 | 95.81% |
| 2023-12-19 | 18 | $140 | $43 | $89.631 | $46.15 | 94.22% |
The Trend in the Analyst Price Target
RARE's average price target has moved down $27.64 over the prior 16 months.
Over the past 49 weeks, RARE's average upside potential has been 122.19%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-01-27 | 15 | 143 | 48 | 92.823 | 43.72 | 112.31% |
| 2023-02-27 | 15 | 142 | 47 | 91.588 | 43.46 | 110.74% |
| 2023-06-06 | 17 | 142 | 48 | 92.000 | 51.48 | 78.71% |
| 2023-06-28 | 17 | 140 | 50 | 92.777 | 48.01 | 93.25% |
| 2023-07-24 | 17 | 140 | 49 | 92.666 | 42.12 | 120% |
RARE Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.22 | 16 | 0 | 2 | 0 | 0 | 18 |
The Trend in the Broker Recommendations
Over the past 41 months, RARE's average broker recommendation rating improved by 0.28.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- In terms of how ULTRAGENYX PHARMACEUTICAL INC fares relative to all US stocks, note that its variance in analysts' estimates is lower than -4987.33% of that group.
- In the context of stocks in the large market cap category, ULTRAGENYX PHARMACEUTICAL INC's upside potential (average analyst target price relative to current price) is greater than 5329.1% of them.
- ULTRAGENYX PHARMACEUTICAL INC's number of analysts covering the stock is higher than 5059.6% of Pharmaceutical Products stocks.
- ULTRAGENYX PHARMACEUTICAL INC's average analyst price target is higher than 4989.36% of Pharmaceutical Products stocks.
Stocks similar to ULTRAGENYX PHARMACEUTICAL INC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are CTLT, TEVA, and PRGO.
View All Top Stocks by Price Target
Is RARE a Buy, Hold or Sell? See the POWR Ratings now!